Blinatumomab, a CD3/CD19-directed bispecific T-cell engager molecule with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), has been shown to result in B-cell aplasia and hence reduced immunoglobulin levels [37]. Here, CD19 is linked to B-cell acute lymphoblastic leukemia.